US5567607A - Method of producing transgenic animals - Google Patents

Method of producing transgenic animals Download PDF

Info

Publication number
US5567607A
US5567607A US08/424,221 US42422195A US5567607A US 5567607 A US5567607 A US 5567607A US 42422195 A US42422195 A US 42422195A US 5567607 A US5567607 A US 5567607A
Authority
US
United States
Prior art keywords
dna
electric field
pulses
gene
electrode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/424,221
Inventor
Xi Zhao
Tai-Kin Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Incell
Original Assignee
Incell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/142,320 external-priority patent/US4849355A/en
Application filed by Incell filed Critical Incell
Priority to US08/424,221 priority Critical patent/US5567607A/en
Assigned to INCELL reassignment INCELL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TRANSGENIC TECHNOLOGIES, INC.
Application granted granted Critical
Publication of US5567607A publication Critical patent/US5567607A/en
Assigned to CYTO PULSE SCIENCES, INC. reassignment CYTO PULSE SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IN CELL, INC.
Assigned to CELLECTIS S.A. reassignment CELLECTIS S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CYTO PULSE SCIENCES, INC.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Definitions

  • the present invention is a method to transfer of DNA, into embryos to produce transgenic animals.
  • various chemical and mechanical methods have been developed for transferring genetic materials into cells. Chemical methods involve the use of chemicals which permeabilize the cell surface, hence facilitates the transfer of the genetic materials into cells.
  • FIG. 1 is a diagram of an apparatus employed in the preferred embodiment of the invention.
  • FIG. 2 is a diagram of an apparatus employed in a second embodiment of the invention.
  • FIG. 3 is an enlarged view of a preferred receptacle shown in FIG. 1.
  • a solution or suspension containing the DNA to be transferred and the embryo are placed in a receptacle such that one electrode contacts the solution, suspension or mixture below the surface thereof.
  • the said electrode is located at the lowest point of the said receptacle.
  • Juxtaposed above the surface of the solution, suspension or mixture, but not in contact therewith is a second electrode directed towards the surface of the solution, suspension or mixture.
  • the distance between the point of the second electrode and the surface of the solution, suspension or mixture is not critical. A distance of about 0.7 cm to about 4 cm has been used.
  • the electrodes may be connected to a conventional electric field generator.
  • the electric field which may be applied to the solution or suspension containing the cells and gene must be high enough to create a high electric field or electric discharge but not great enough to substantially alter or destroy the cells or the gene. Voltages from approximately 1 kilovolt to 8 kilovolts may be used.
  • the pulse duration of the field varies from about 1 microseconds to 200 microseconds/pulse, usually about 120 microseconds depending on the nature of the target cells.
  • a pulse discharge up to about 120 microseconds/pulse is preferred.
  • These pulses are given in about 0.2 to 3.2 second bursts at a distance of about 0.5 to 3 mm from the mixture.
  • the number of pulses which may be applied to the solution, suspension or mixture containing DNA may vary from about 2 4 to about 2 11 , depending upon the pulse width and intensity (amplitude) and the nature of the cells.
  • the amplitude will usually be in the range of about 1-8 kV.
  • the preferred number of pulses is about 2 6 to 2 9 at about 30 to 108 ⁇ S/pulse
  • Preferably about 2 9 pulses are used with a width of 120 ⁇ S and voltage intensity of about 3 kV.
  • a conventional electric field generator 10 having a control and monitoring means 11 for applying field or pulse and an intensity control and measuring means 12 for voltage.
  • a conventional generator is available, for example, from Andy Hish Associates, Van Nuys, Model Number ESD255 Electrostatic Discharge Generator with probe P255-1.
  • Probe 13 is connected to said generator 10 and vertically disposed above vial receptacle 15. At the lowest point of vial receptacle 15 is located a ground electrode 14.
  • Vial receptacle 15 contains a solution or suspension of cells and genes. As shown, vial receptacle 15 may be conical in shape and the ground electrode 14 is located at the apex thereof.
  • vial receptacle 15 may be preferred since there may be a concentration gradient of cells within the solution or suspension 16 due to the heterogeneity of the cells and in such case the gradient concentration of cells may be near the apex of vial receptacle 15.
  • a preferred apparatus embodying the features of FIG. 1 is the BAEKON 2000, manufactured by Baekon, Inc., 20333 Merida Drive, Saratoga, Calif., and which is described in U.S. Pat. No. 4,663,292, incorporated by reference herein.
  • FIG. 2 there is shown a second embodiment of the invention.
  • FIG. 2 is similar to FIG. 1 except that receptacle 17 is a tube with a round bottom having the ground electrode located at the lowest point of the tube.
  • FIG. 3 there is shown an enlarged view of vial receptacle 15.
  • a probe 13 is directed towards the surface 18 of the solution or suspension containing the cells and genes. Both the probe 13 and the vial 15 containing solution 16 may be exposed to the atmosphere during the experiment. It is readily apparent that the vial 15 need not be completely filled as shown in order to perform the experiment. A requirement is that the cells and gene containing solution or suspension is placed between direct discharge or electric field from probe 13 to ground electrode 14.
  • DNA including genes, may be transferred into embryo of animals or humans.
  • growth hormone genes for example, growth hormone genes, insulin genes, Hepatitis B surface antigen genes, erthropoietin genes, lymphokine genes, urokinase genes, etc.
  • genes which may be transferred according to the present invention may be structural genes, i.e., DNA fragments comprising the gene, or may be genes on vectors, such as, plasmid vectors, cosmid vectors, phage vectors, viral vectors, etc.
  • the present invention may be utilized to produce animals having improved genetic characteristics, such as the growth rate, coloration and patterning, disease resistance, drug tolerance, etc.
  • the machine was set at amplitude 3.5 kV, number of pulses at 512, pulse time at 102 uS, burst time at 0.8 sec, cycles at 5, and non-contact mode of operation with 1 mm between the positive electrode and the meniscus of the gene-embryo mixture. Two more samples were similarly treated. After exposure to the treatment, the embryos were washed twice with M2 medium, and cultured to 2-cell stage in M16 medium at 37° C. in a humidified atmosphere of 5% CO 2 in air. Embryos were reimplanted into pseudo-pregnant female mice. Out of a total 280 embryos in three samples, 95 baby mice were born, of which 19 showed positive integration of the DNA into the genome as detected by hybridization.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A method is provided for making transgenic animals by transferring DNA into embryo by subjecting the mixture of the DNA to be transferred and the embryo to an electric discharge.

Description

This is a continuation of application Ser. No. 08/291,136 (now abandoned), filed Aug. 16, 1994, which is a continuation of application Ser. No. 08/059,180 (now abandoned), filed May 6, 1993, which is a continuation of Ser. No. 07/475,726 (now abandoned), filed Feb. 6, 1990, which is a CIP of 07/215,670 (now abandoned) filed Jul. 6, 1988; which is a CIP of Ser. No. 07/142,320 filed Dec. 30, 1987, now U.S. Pat. No. 4,849,355 which is a continuation of Ser. No. 06,689,657 now abandoned, filed Jan. 8, 19985; which is a CIP of Ser. No. 06/315,944, (now abandoned) filed Oct. 28, 1981.
The present invention is a method to transfer of DNA, into embryos to produce transgenic animals. In the fields of genetic engineering, cell biology, and embryo manipulation, various chemical and mechanical methods have been developed for transferring genetic materials into cells. Chemical methods involve the use of chemicals which permeabilize the cell surface, hence facilitates the transfer of the genetic materials into cells. [For reviews, see: Gerard Venema "Bacterial Transformation" in Adv. Microbiol. Physl. (1979) 19: 245-331; George Scangos and Frank H. Ruddle "Mechanisms and Applications of DNA-mediated Gene Transfer in Mammalian Cells--A Review" in Gene (1981) 14: 1-10; O. Wesley McBride and Jane L. Peterson "Chromosome-mediated Gene Transfer in Mammalian Cells" in Ann. Rev. Genet. (1980) 14: 321-345; Jurgen Horst et al., "On Procaryotic Gene Expression in Eucaryotic Systems" in Human Genetics (1980) 54: 289-302; R. Fraley and D. Papahadjopoulos, "New Generation Liposomes; The Engineering of an Efficient Vehicle for Intracellular Delivery of Nucleic Acids" in Trends Biochem. Sci. (1981) March. pp. 77-80.] Mechanical methods involve the injection of genetic materials directly into the cells, commonly known as microinjection (For review, see: W. French Anderson and Elaine G. Diacumakos "Genetic Engineering in Mammalian Cells" in Scientific American (1981) 245: 106-121).
In procaryotic systems, the chemical methods of transferring genes are usually employed, whereas in eucaryotic systems, both the chemical and mechanical methods are used.
All available methods, however, are somewhat dependent upon both the gene which is to be transferred and the recipient cells. Methods which may be used to transfer genes into procaryotes may not work in transferring genes into eucaryotes. However, according to the present invention, a single method is provided which may be utilized to transfer genes into either procaryotic or eucaryotic cells.
FIG. 1 is a diagram of an apparatus employed in the preferred embodiment of the invention.
FIG. 2 is a diagram of an apparatus employed in a second embodiment of the invention.
FIG. 3 is an enlarged view of a preferred receptacle shown in FIG. 1.
According to the present invention a solution or suspension containing the DNA to be transferred and the embryo are placed in a receptacle such that one electrode contacts the solution, suspension or mixture below the surface thereof. Preferably the said electrode is located at the lowest point of the said receptacle. Juxtaposed above the surface of the solution, suspension or mixture, but not in contact therewith is a second electrode directed towards the surface of the solution, suspension or mixture. The distance between the point of the second electrode and the surface of the solution, suspension or mixture is not critical. A distance of about 0.7 cm to about 4 cm has been used.
The electrodes may be connected to a conventional electric field generator. The electric field which may be applied to the solution or suspension containing the cells and gene must be high enough to create a high electric field or electric discharge but not great enough to substantially alter or destroy the cells or the gene. Voltages from approximately 1 kilovolt to 8 kilovolts may be used.
When an electric field is applied to the gene-embryo mixture, the pulse duration of the field varies from about 1 microseconds to 200 microseconds/pulse, usually about 120 microseconds depending on the nature of the target cells. When discharge condition is employed, a pulse discharge up to about 120 microseconds/pulse is preferred. These pulses are given in about 0.2 to 3.2 second bursts at a distance of about 0.5 to 3 mm from the mixture. The number of pulses which may be applied to the solution, suspension or mixture containing DNA may vary from about 24 to about 211, depending upon the pulse width and intensity (amplitude) and the nature of the cells. The amplitude will usually be in the range of about 1-8 kV. The preferred number of pulses is about 26 to 29 at about 30 to 108 μS/pulse Preferably about 29 pulses are used with a width of 120 μS and voltage intensity of about 3 kV.
Referring to FIG. 1, there is shown a conventional electric field generator 10 having a control and monitoring means 11 for applying field or pulse and an intensity control and measuring means 12 for voltage. Such a conventional generator is available, for example, from Andy Hish Associates, Van Nuys, Model Number ESD255 Electrostatic Discharge Generator with probe P255-1. Probe 13 is connected to said generator 10 and vertically disposed above vial receptacle 15. At the lowest point of vial receptacle 15 is located a ground electrode 14. Vial receptacle 15 contains a solution or suspension of cells and genes. As shown, vial receptacle 15 may be conical in shape and the ground electrode 14 is located at the apex thereof. Without limiting the invention to any particular theory, the shape of vial receptacle 15 may be preferred since there may be a concentration gradient of cells within the solution or suspension 16 due to the heterogeneity of the cells and in such case the gradient concentration of cells may be near the apex of vial receptacle 15. A preferred apparatus embodying the features of FIG. 1 is the BAEKON 2000, manufactured by Baekon, Inc., 20333 Merida Drive, Saratoga, Calif., and which is described in U.S. Pat. No. 4,663,292, incorporated by reference herein.
Referring to FIG. 2 there is shown a second embodiment of the invention. FIG. 2 is similar to FIG. 1 except that receptacle 17 is a tube with a round bottom having the ground electrode located at the lowest point of the tube.
Referring to FIG. 3 there is shown an enlarged view of vial receptacle 15. As shown, a probe 13 is directed towards the surface 18 of the solution or suspension containing the cells and genes. Both the probe 13 and the vial 15 containing solution 16 may be exposed to the atmosphere during the experiment. It is readily apparent that the vial 15 need not be completely filled as shown in order to perform the experiment. A requirement is that the cells and gene containing solution or suspension is placed between direct discharge or electric field from probe 13 to ground electrode 14.
According to the present invention DNA, including genes, may be transferred into embryo of animals or humans. For example, growth hormone genes, insulin genes, Hepatitis B surface antigen genes, erthropoietin genes, lymphokine genes, urokinase genes, etc.
The genes which may be transferred according to the present invention may be structural genes, i.e., DNA fragments comprising the gene, or may be genes on vectors, such as, plasmid vectors, cosmid vectors, phage vectors, viral vectors, etc.
The present invention may be utilized to produce animals having improved genetic characteristics, such as the growth rate, coloration and patterning, disease resistance, drug tolerance, etc.
For purposes of illustrating the present invention the following examples are provided. However, the scope of the invention is not intended to be limited thereto.
EXAMPLE Gene Transfer into Mouse Embryo
Into the receptacle of the Baekon 2000 Advanced Macromolecule Transfer System were mixed 100 embryos (1-cell stage) of BDF-1 strain of mouse in 100 ul of a sterilized buffer M2 comprising 94.66 mM NaCl, 4.78 mM KCl, 1.71 mM CaCl2, 1.19 mM KH2 PO4, 1.19 mM MgSO4, 4.15 mM NaHCO3, 20.85 mM Hepes, 23.28 mM Na-Lactate, 0.33 nM Na-pyruvate, 5.56 nM Glucose, 100 Unit/ml penicillin and streptomycin, 0.1% phenol red, and 10 ug of DNA of growth hormone gene from porcine. The machine was set at amplitude 3.5 kV, number of pulses at 512, pulse time at 102 uS, burst time at 0.8 sec, cycles at 5, and non-contact mode of operation with 1 mm between the positive electrode and the meniscus of the gene-embryo mixture. Two more samples were similarly treated. After exposure to the treatment, the embryos were washed twice with M2 medium, and cultured to 2-cell stage in M16 medium at 37° C. in a humidified atmosphere of 5% CO2 in air. Embryos were reimplanted into pseudo-pregnant female mice. Out of a total 280 embryos in three samples, 95 baby mice were born, of which 19 showed positive integration of the DNA into the genome as detected by hybridization.

Claims (13)

What is claimed is:
1. A method for transferring DNA into fertilized eggs of a non-human mammal, comprising: subjecting a mixture of said DNA and said fertilized eggs to pulses of an electric field for a time sufficient to effect transfer of said DNA to said fertilized eggs.
2. The method according to claim 1 wherein said electric field is provided by a first and a second electrode having a voltage between said first and said second electrode of from approximately 3 (kv) to 20 Kilovolts.
3. A method according to claim 1 wherein said DNA comprises at least one gene.
4. A method according to claim 1 wherein said DNA is transferred into said fertilized eggs on a vector.
5. A method according to claim 1 wherein said pulses comprise 26 to 29 pulses.
6. A method according to claim 1 wherein said electric field is maintained for a duration of from about 1 second to 90 seconds.
7. A method according to claim 1 wherein said fertilzed eggs are from a mouse.
8. A method for transferring DNA into an oocyte of a nonhuman mammal, comprising: subjecting a mixture of said DNA and said oocyte to pulses of an electric field for a time sufficient to effect transfer of said DNA to said oocyte.
9. The method according to claim 8, wherein said electric field is provided by a first and a second electrode having a voltage between said first and said second electrode of from approximately 3 to 20 kilovolts.
10. A method according to claim 8, wherein said DNA comprises at least one gene.
11. A method according to claim 8, wherein said DNA is transferred into said oocyte on a vector.
12. A method according to claim 8, wherein said pulses comprise 26 to 29 pulses.
13. A method according to claim 8, wherein said electric field is maintained for a duration of from about 1 second to 90 seconds.
US08/424,221 1981-10-28 1995-04-19 Method of producing transgenic animals Expired - Fee Related US5567607A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/424,221 US5567607A (en) 1981-10-28 1995-04-19 Method of producing transgenic animals

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US31594481A 1981-10-28 1981-10-28
US68965785A 1985-01-08 1985-01-08
US07/142,320 US4849355A (en) 1985-01-08 1987-12-30 Method of transferring genes into cells
US21567088A 1988-07-06 1988-07-06
US47572690A 1990-02-06 1990-02-06
US5918093A 1993-05-06 1993-05-06
US29113694A 1994-08-16 1994-08-16
US08/424,221 US5567607A (en) 1981-10-28 1995-04-19 Method of producing transgenic animals

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US29113694A Continuation 1981-10-28 1994-08-16

Publications (1)

Publication Number Publication Date
US5567607A true US5567607A (en) 1996-10-22

Family

ID=27568154

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/424,221 Expired - Fee Related US5567607A (en) 1981-10-28 1995-04-19 Method of producing transgenic animals

Country Status (1)

Country Link
US (1) US5567607A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020178456A1 (en) * 1999-02-05 2002-11-28 Jens-Ulrich Buelow Human polyclonal antibodies from genetically engineered animals
US20030017534A1 (en) * 2000-08-03 2003-01-23 Roland Buelow Production of humanized antibodies in transgenic animals
US20030100490A1 (en) * 1999-04-01 2003-05-29 Tony Cruz Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20030157684A1 (en) * 1997-09-09 2003-08-21 Cambia Microbial B-glucuronidase genes, gene production and uses thereof
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US20080184380A1 (en) * 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US11230697B2 (en) 2006-09-01 2022-01-25 Therapeutic Human Polyclonals Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663292A (en) * 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4663292A (en) * 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Asubel et al. (eds.) 1988, in: Current Protocols in Molecular Biology (vol. 2), John Wiley & Sons, New York, NY, appendix p. A.2.3. *
Berg et al. 1984 Bioelectrochem. Bioenerget. 12, 119 133. *
Berg et al. 1984 Bioelectrochem. Bioenerget. 12, 119-133.
Hogan et al. 686 in: Manipulating the Main Embryo. A Laboratory Manual. Cold Spring Harbor Laboratory, NY. pp. 153 154. *
Hogan et al. 686 in: Manipulating the Main Embryo. A Laboratory Manual. Cold Spring Harbor Laboratory, NY. pp. 153-154.
Nemec et al. 1989 Theriogenology 31, 233. *
Old et al. 1985 in: Principles of Gene Manipulation An Introduction to Genetic Engineering. Blackwell Sci. Publ., Oxford Eng. pp. 262 265. *
Old et al. 1985 in: Principles of Gene Manipulation An Introduction to Genetic Engineering. Blackwell Sci. Publ., Oxford Eng. pp. 262-265.
Robl et al. 1986 Thenogenobgy 25, 189. *
Uize et al. 1987 Gene 55, 339 344. *
Uize et al. 1987 Gene 55, 339-344.
Webster s II New Riverside University Dictionary, Soukhanov et al. (ed.) 1984, Houghton Mifflin Company, Boston, MA, pp. 67 and 119 120. *
Webster s Third New International Dictionary, 1963, G & C Marriam Company Ma. p. 740. *
Webster's II New Riverside University Dictionary, Soukhanov et al. (ed.) 1984, Houghton Mifflin Company, Boston, MA, pp. 67 and 119-120.
Webster's Third New International Dictionary, 1963, G & C Marriam Company Ma. p. 740.

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US7141719B2 (en) 1997-09-09 2006-11-28 Cambia Microbial β-Glucuronidase genes, gene production and uses thereof
US20030157684A1 (en) * 1997-09-09 2003-08-21 Cambia Microbial B-glucuronidase genes, gene production and uses thereof
US20080299112A1 (en) * 1999-02-05 2008-12-04 Jens-Ulrich Buelow Human Polyclonal Antibodies from Genetically Engineered Animals
US20020178456A1 (en) * 1999-02-05 2002-11-28 Jens-Ulrich Buelow Human polyclonal antibodies from genetically engineered animals
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20050065085A1 (en) * 1999-04-01 2005-03-24 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20050058646A1 (en) * 1999-04-01 2005-03-17 Turley Eva A. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyalurons
US20030100490A1 (en) * 1999-04-01 2003-05-29 Tony Cruz Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US20070092505A1 (en) * 2000-08-03 2007-04-26 Roland Buelow Production of humanized antibodies in transgenic animals
US20030017534A1 (en) * 2000-08-03 2003-01-23 Roland Buelow Production of humanized antibodies in transgenic animals
EP2044839A2 (en) 2000-08-03 2009-04-08 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US20080184380A1 (en) * 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
US11230697B2 (en) 2006-09-01 2022-01-25 Therapeutic Human Polyclonals Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies

Similar Documents

Publication Publication Date Title
US4849355A (en) Method of transferring genes into cells
Co et al. Generation of transgenic mice and germline transmission of a mammalian artificial chromosome introduced into embryos by pronuclear microinjection
US4664097A (en) Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion
US6204433B1 (en) Microinjection methods to transform arthropods with exogenous DNA
US9982251B2 (en) Large volume ex vivo electroporation method
US5567607A (en) Method of producing transgenic animals
Kubiak et al. Electrofusion of mouse blastomeres
Crooijmans et al. Two-dimensional screening of the Wageningen chicken BAC library
Shizuya et al. Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector.
Buttin et al. Enzymatic DNA degradation in E. coli: its relationship to synthetic processes at the chromosome level
US6376743B1 (en) Mammalian transgenesis by intracytoplasmic sperm injection
Sundararajan et al. Transposable element interactions in insects: crossmobilization of hobo and Hermes
US20020081739A1 (en) Particle-mediated transformation of animal somatic cells
AU7037881A (en) Processes for inserting dna into eucaryotic cells and for producing proteinaceous materials
CN105018523B (en) A ZB transposon system and its mediated gene transfer method
US20020046414A1 (en) In vivo electroporation method for early stage embryo of aves
EP1141265B1 (en) Double nuclear transfer method and results thereof
Weber et al. Genetic manipulation of plant cells and organelles with a laser microbeam
Kaneko et al. Creating knockout and knockin rodents using engineered endonucleases via direct embryo injection
Rossolini et al. Kluyveromyces lactis rDNA as a target for multiple integration by homologous recombination
Hattermann et al. Efficient DNA transformation of Bradyrhizobium japonicum by electroporation
Leopold et al. Using electroporation and a slot cuvette to deliver plasmid DNA to insect embryos
CA1208146A (en) Method of transferring genes into cells
Knecht et al. Quantification of transformation efficiency using a new method for clonal growth and selection of axenic Dictyostelium cells
Shattuck-Eidens et al. Molecular cloning of the uhp region and evidence for a positive activator for expression of the hexose phosphate transport system of Escherichia coli

Legal Events

Date Code Title Description
AS Assignment

Owner name: INCELL, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSGENIC TECHNOLOGIES, INC.;REEL/FRAME:007967/0472

Effective date: 19960523

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FP Lapsed due to failure to pay maintenance fee

Effective date: 20001022

PRDP Patent reinstated due to the acceptance of a late maintenance fee

Effective date: 20001208

AS Assignment

Owner name: CYTO PULSE SCIENCES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IN CELL, INC.;REEL/FRAME:012025/0348

Effective date: 20010516

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20041022

AS Assignment

Owner name: CELLECTIS S.A., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CYTO PULSE SCIENCES, INC.;REEL/FRAME:025169/0621

Effective date: 20100901